Default: Seminars in Thrombosis and Hemostasis

ISSN: 0094-6176

Journal Home

Journal Guideline

Seminars in Thrombosis and Hemostasis Q1 Unclaimed

Thieme Medical Publishers Inc. United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Seminars in Thrombosis and Hemostasis is a journal indexed in SJR in Hematology and Cardiology and Cardiovascular Medicine with an H index of 107. It has an SJR impact factor of 1,19 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,19.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Seminars in Thrombosis and Hemostasis

1,19

SJR Impact factor

107

H Index

135

Total Docs (Last Year)

331

Total Docs (3 years)

9181

Total Refs

1383

Total Cites (3 years)

258

Citable Docs (3 years)

4.05

Cites/Doc (2 years)

68.01

Ref/Doc

Comments

No comments ... Be the first to comment!



Best articles by citations

Factor Xa Is a Superior Target to Factor IIa for Antithrombotic Therapies

View more

Venous Thromboembolism and Its Treatment in High-Risk Groups

View more

A Reliable von Willebrand Factor: Ristocetin Cofactor Enzyme-Linked Immunosorbent Assay to Differentiate between Type 1 and Type 2 von Willebrand Disease

View more

Anticoagulants in Thrombosis and Cancer: The Missing Link

View more

Venous Thromboembolism in Medical Patients-The Scope of the Problem

View more

Clinical Aspects of the Different Forms of Viral Hepatitis and Their Treatment

View more

Virus Safety of Hemophilia Treatment in Germany and Austria-a Review of the Past 15 Years: A Eulogy for the 70th birthday of Professor Dr. rer. nat. Norbert Heimburger

View more

Virus Safety of Hemophilia Treatment in Germany and Austria: A Tribute to Norbert Heimburger, Ph.D.

View more

Virus Safety of Pasteurized Clotting Factor Concentrates

View more

Development of Direct Thrombin Inhibitors in Comparison with Glycosaminoglycans

View more

Low-Molecular-Weight Heparin or Oral Anticoagulation for Secondary Prevention of Deep Vein Thrombosis in Cancer Patients

View more

Low-Molecular-Weight Heparins: Beyond Thrombosis in the Management of the Cancer Patient

View more
SHOW MORE ARTICLES

Greetings from the German Hemophilia Society and from the Gesellschaft fur Thrombose- und Hämostaseforschung

View more

von Willebrand Factor Collagen-Binding (Activity) Assay in the Diagnosis of von Willebrand Disease: A 15-Year Journey

View more

Successful Treatment of Patients with von Willebrand Disease using a High-Purity Double-Virus Inactivated Factor VIII/von Willebrand Factor Concentrate (Immunate®)

View more

Upper Extremity Deep Venous Thrombosis

View more

MALDI Mass Spectrometry as a Tool for Characterizing Glycosaminoglycan Oligosaccharides and their Interaction with Proteins

View more

Prevention of Venous Thromboembolism: Focus on Mechanical Prophylaxis

View more

Reduction in Thrombus Extension and Clinical End Points in Patients after Initial Treatment for Deep Vein Thrombosis with the Fixed-Dose Body Weight-Independent Low Molecular Weight Heparin Certoparin

View more

Alterations in Fibrin Structure in Patients with Liver Diseases

View more

Antithrombin Attenuates Microvascular Leakage and Leukocyte-Endothelial Interaction in Response to Endotoxin

View more

Sixteen Years of Treatment with Pasteurized Human Clotting Factor Concentrates in Children and Adolescents: A Pharmacosurveillance Investigation Comprising 727 Patient Years

View more

Regulatory Role of Cytokines in Disseminated Intravascular Coagulation

View more

Molecular Weight-Dependent Influence of Heparin on the Form of Tissue Factor Pathway Inhibitor Circulating in Plasma

View more

FAQS